Ronald J Hogg
Scott & White Clinic, Temple, TX, United States Of America | Baylor Scott and White Healthcare, Temple, TX | Scott & White Clinic, Temple, Texas, United States of America | ...
KOL Resume for Ronald J Hogg
Scott & White Clinic, Temple, TX, United States Of America
Scott & White Clinic, Temple, Texas, United States of America
Scott & White Clinic, Temple, TX, USA
Due to the number of contributing authors, the affiliations are provided in the Supplemental Material
Department of Pediatrics, The Children's Hospital at Scott White, Temple, Texas, USA
The Children’s Hospital at Scott White Medical Center, Department of Pediatrics, Temple, Texas, USA
Department of Pediatrics, The Children’s Hospital, Scott and White Memorial Hospital and Clinic, and the Scott, Sherwood and Brindley Foundation and Texas A&M College of Medicine, 2401 South 31st Street, Temple, Texas 76508 USA
The Children's Hospital at Scott & White, Temple, Texas
St. Joseph’s Hospital & Medical Center, 222 W. Thomas Rd., Suite 410, 85013, Phoenix, AZ, USA
*St. Joseph’s Hospital and Medical Center, Phoenix, Arizona; †Department of Clinical Research, Medical City Dallas Hospital, Dallas, Texas; and ‡A.T. Still University, Mesa, Arizona
Medical City Dallas Hospital, Dallas, TX
Division of Pediatric Nephrology St. Joseph's Hospital and Medical Center, 2346 North Central Avenue, Phoenix, AZ 85004, USA
Department of Pediatrics, Medical City Dallas Hospital, Dallas, TX, USA
From the Duke Clinical Research Institute (J.S.L., K.B., R.K., R.M.C.), Duke University Medical Center, Durham, NC; Impact Clinical Trials (L.H.), Los Angeles, Calif; University of Texas at Houston Medical School (R.P.), Houston; Medical City Dallas Hospital (R.H.), Tex; Northwest Pediatric Kidney Specialists (R.D.J.), Portland, Ore; Children’s Hospital of Pittsburgh (P.K.), Pa; Pediatric Cardiology (C.M.C), PSC, Lexington, Ky; Children’s Hospital of Michigan (T.K.M.), Detroit; Smolensk State Medical Academy (L.Z., L.K.), Russia; Western Galilee Hospital (I.W.), Nahariya, Israel; and Bristol-Myers Squibb Company (D.D.), Princeton, NJ.
North Texas Hospital for Children, Dallas, Texas, USA
Department of Pediatrics, Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University School of Medicine, Baltimore, Maryland; The Hospital for Sick Children, Toronto, Ontario, Canada; the Department of Pediatrics, Columbia Hospital at Medical City, Dallas, Texas; and Merck & Co, Inc, Blue Bell, Pennsylvania
Department of Pediatrics, Columbia Hospital at Medical City, Dallas Texas, USA
University of Washington and Children's Hospital, Seattle, WA; University of Texas Southwestern Medical Center; Medical City Dallas Hospital, Dallas; Baylor College of Medicine, Houston, TX; and Merck Research Laboratories, West Point, PA.
Instituto Nacional de Salud Nino, Lima, Peru
Luis Calvo Mackenna Hospital, Santiago, Chile
Division of Pediatric Nephrology, North Texas Hospital for Children at Medical City Dallas Hospital, Dallas, TX, USA, US
North Texas Hospital for Children, Medical City Dallas Hospital, Dallas, Texas
Merck Research Labs, West Point, PA, USA
From North Texas Hospital for Children at Medical City Dallas, Dallas, Texas;
Stanford University Medical School, Stanford, California
Diagnostic Systems Laboratories, Inc., Webster, Texas
University of Washington, Seattle, Washington
Department of Pediatrics, Medical City Dallas Hospital, TX 75230-2518, USA.
Southwest Pediatric Nephrology Study Group, Baylor University Medical Center, Dallas, Tex., USA.
SPNSG Central Office, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX, USA
Southwest Pediatric Nephrology Study Group, Department of Pediatrics, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX, USA
University of California, San Francisco, San Francisco, California
Department of Pediatrics, Baylor University Medical Center, 3500 Gaston Avenue, 75246, Dallas, TX
Southwest Pediatric Nephrology Study Group, Baylor University Medical Center, Dallas, Texas, USA
Baylor University Medical Center, Dallas, Texas, USA
From the Department of Pediatrics, Baylor University Medical Center, Dallas.
Baylor University Medical Center, Dallas, TX 75246.
Department of Pediatrics, University of Texas Health Science Center and Baylor University Medical Center, Dallas, Texas, USA
Southwest Pediatric Nephrology Study Group Central Office, Department of Pediatrics, University of Texas Health Science Center at Dallas, 5323 Harry Hines Boulevard, Dallas, Texas 75235, USA
Departments of Pediatrics and Pediatric Surgery, University of Texas Health Science Center at Dallas.
Department of Pediatrics, The University of Texas Health Science Center at Dallas, Dallas
Ronald J Hogg: Influence Statistics
|emphasis iga nephropathy||#1|
|persistent proteinuria degrees||#1|
|epidemiology aspects children||#1|
|twh publication catheters||#1|
|fos omacor patients||#1|
|23 tenckhoff catheters||#1|
|proteinuria 21 24||#1|
|adolescents renal biopsy||#1|
|study meetings success||#1|
|outcome markers studies||#1|
|iga igg onset||#1|
|adolescents immunoglobulin nephropathy||#1|
|question institutional credit||#1|
|urinary screening programs||#1|
|18 living donor||#1|
|mass screening ckd||#1|
|13 lrd allografts||#1|
|igan urinary ratio||#1|
|26 transplants catheters||#1|
|topic female glomerulosclerosis||#1|
|hypercellularity electrondense deposits||#1|
|pediatric nephrologist humans||#1|
Open the FULL List in Excel
Prominent publications by Ronald J Hogg
Modulation of growth factors by growth hormone in children with chronic renal failure
[ PUBLICATION ]
Anthropometric measurements and circulating growth factors were studied serially in 44 prepubertal children with growth failure and chronic renal failure (GFR = 10 to 40 ml/min/1.73 m2) who were randomized to receive either recombinant human growth hormone (rhGH; N = 30) or no treatment (N = 14). RhGH was given as Nutropin, 0.05 mg/kg/day, and the studies were carried out at baseline and after 3 and 12 months. At baseline, serum insulin-like growth factor binding protein (IGFBP)-1 and -2 ...
|Known for Growth Factor | Chronic Renal | Serum Levels | 12 Months | Rhgh Treatment|
Individual Variation in Lipidomic Profiles of Healthy Subjects in Response to Omega-3 Fatty Acids
[ PUBLICATION ]
INTRODUCTION: Conflicting findings in both interventional and observational studies have resulted in a lack of consensus on the benefits of ω3 fatty acids in reducing disease risk. This may be due to individual variability in response. We used a multi-platform lipidomic approach to investigate both the consistent and inconsistent responses of individuals comprehensively to a defined ω3 intervention.
METHODS: The lipidomic profile including fatty acids, lipid classes, lipoprotein ...
|Known for Fatty Acids | Lipidomic Profiles | Epa Dha | Individual Variability | Docosahexaenoic Acid|
Continuous ambulatory and continuous cycling peritoneal dialysis in children. A report of the Southwest Pediatric Nephrology Study Group1
[ PUBLICATION ]
Continuous ambulatory peritoneal dialysis (CAPD) and continuous cycling peritoneal dialysis (CCPD) have become acceptable methods of treatment for children with endstage renal disease (ESRD). In this study we have compared the effectiveness of these two modalities of prolonged dwell peritoneal dialysis in 82 children treated at home with CAPD and/or CCPD for a mean of 10.2 months. Forty variables were evaluated during 92 patient periods (63 CAPD, 29 CCPD). There was no difference between ...
|Known for Continuous Ambulatory | Peritoneal Dialysis | Capd Ccpd | Growth Children | Pediatric Nephrology|
Forty children with hypertension between the age of 2 months and 15 years received 0.07 to 0.14 mg/kg of enalapril as a single daily dose. Enalapril was administered orally as a novel extemporaneous suspension in children younger than 6 years of age and as tablets in older children. First-dose and steady-state pharmacokinetics were estimated in children ages 1 to 24 months, 25 months to < 6 years, 6 to < 12 years, and 12 to < 16 years. Maximum serum concentrations for enalapril occurred ...
|Known for Enalapril Children | 6 Years | Active Metabolite | Antihypertensive Agents | Humans Hypertension|
Serum levels of galactose-deficient IgA in children with IgA nephropathy and Henoch-Schönlein purpura
[ PUBLICATION ]
IgA nephropathy and Henoch-Schönlein purpura nephritis (HSPN) are related diseases characterized by deposits of IgA1-containing immune complexes in the renal mesangium. Adult patients with IgA nephropathy have aberrantly glycosylated IgA1 (galactose-deficient O-linked glycans) in the circulation and renal deposits. However, IgA1 glycosylation has not been studied in pediatric patients with IgA nephropathy. Using our quantitative lectin enzyme-linked immunosorbent assay (ELISA) test, we ...
|Known for Iga Nephropathy | Serum Levels | Schönlein Purpura | Pediatric Patients | Renal Deposits|
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life
[ PUBLICATION ]
Optimal therapy of patients with steroid-resistant primary focal segmental glomerulosclerosis (FSGS) remains controversial. This report describes the initial study design, baseline characteristics, and quality of life of patients enrolled in the FSGS Clinical Trial, a large multicenter randomized study of this glomerulopathy comparing a 12-month regimen of cyclosporine to the combination of mycophenolate mofetil and oral dexamethasone. Patients with age ranging 2-40 years, with an ...
|Known for Focal Segmental | Quality Life | Patients Fsgs | Immunosuppressive Agents | United States|
Serial measurements of GFR in infants using the continuous iothalamate infusion technique
[ PUBLICATION ]
We undertook a preliminary study to determine if a clinical trial was feasible that would compare the effect of a low protein vs a control formula on GFR and growth in infants with congenital renal insufficiency (CIo < 55 ml/min/1.73 m2). In this report from the Infant Diet Protein Study, we describe validation of a method using the plasma clearance of iothalamate (CIo) as an estimate of glomerular filtration rate (GFR) and results of the preliminary study relating to renal function. The ...
|Known for Gfr Cio | Plasma Clearance | Low Protein | Clinical Trial | Renal Function|
Randomized Controlled Trial of Mycophenolate Mofetil in Children, Adolescents, and Adults With IgA Nephropathy
[ PUBLICATION ]
BACKGROUND: Previous randomized controlled trials evaluating the efficacy of mycophenolate mofetil (MMF) in patients with immunoglobulin A nephropathy (IgAN) have produced varying results.
STUDY DESIGN: Double-blind placebo-controlled randomized controlled trial.
SETTING & PARTICIPANTS: 52 children, adolescents, and adults with biopsy-proven IgAN in 30 centers in the United States and Canada. Entry criteria: age older than 7 to younger than 70 years; urine protein-creatinine ratio ...
|Known for Mycophenolate Mofetil | Iga Nephropathy | Randomized Controlled | 95 Mmf | 6 Months|
Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the Southwest Pediatric Nephrology Study Group1
[ PUBLICATION ]
Clinicopathologic correlations were examined in 75 children with focal segmental glomerulosclerosis (FSGS) associated with idiopathic nephrotic syndrome. The biopsy specimens of all patients were examined by electron microscopy (69 patients) or immunofluorescence microscopy (67 patients) in addition to light microscopy. Fifty-three patients (group A) had FSGS diagnosed on their first biopsy; 22 patients (group B) had one to three previous biopsies showing minimal glomerular changes or ...
|Known for Focal Segmental | Children Fsgs | Chronic Kidney | Idiopathic Nephrotic | Electron Microscopy|
OBJECTIVES: Evaluation of the efficacy and safety of amlodipine in hypertensive children.
STUDY DESIGN: A randomized, double blinded, placebo-controlled, parallel-group, dose-ranging study was conducted at 49 centers in North and South America. The primary end point was the effect of amlodipine on systolic blood pressure (BP); secondary end points included the effect of amlodipine on diastolic BP, the effect of amlodipine as a function of dose and body size, and evaluation of ...
|Known for Hypertensive Children | Safety Amlodipine | Primary Hypertension | Systolic Diastolic | Schedule Female Humans|
PURPOSE: To determine the incidence of avascular necrosis (AVN) of the femoral head in children with chronic renal failure.
MATERIALS AND METHODS: Pelvic radiographs in 205 children (age range, 6 months to 16 years; mean age, 6 years +/- 3.5 [SD]) with chronic renal failure were reviewed. Serial radiographs were obtained every 6 months for 1-7 years (mean, 3 years +/- 2) to assess the presence of AVN of the femoral head; six children had metabolic renal disease, 21 had acquired renal ...
|Known for Femoral Head | Renal Disease | Avascular Necrosis | Children Chronic | Growth Hormone Therapy|
Key People For Iga Nephropathy
Ronald J Hogg:Expert Impact
Concepts for whichRonald J Hogghas direct influence:Iga nephropathy, Serum levels, Nephrotic syndrome, Binding protein, Chronic kidney disease, Chronic renal failure, Multicenter studies, Hypertensive children.
Ronald J Hogg:KOL impact
Concepts related to the work of other authors for whichfor which Ronald J Hogg has influence:Chronic kidney disease, Renal function, Nephrotic syndrome, Iga nephropathy, Heart failure, Glomerular filtration, Blood pressure.
Is this your profile? Claim your profile Copy URL Embed Link to your profile